The effect of various concentrations of human recombinant epidermal growth factor on split-thickness skin wounds.

Joon Pio Hong, Yun Wha Kim, Heun Don Jung, Kwon Il Jung
Author Information
  1. Joon Pio Hong: Department of Plastic and Reconstructive Surgery, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Korea. joonphong@amc.seoul.kr

Abstract

Epidermal growth factor (EGF) is a potent stimulant of epithelialisation. However, topical application of EGF to achieve facilitated re-epithelialisation in partial thickness wounds has been controversial. A total of 10 pigs, each with eight 4 x 4 cm partial thickness wounds, were treated twice a day for 10 days to observe the effect of human recombinant EGF in concentrations of 0.1, 1, 5, 10, 25 ug/g, vehicle only and two controls. The control and the vehicle-only wounds each demonstrated 100% healing time (HT100) of 9.31 +/- 1.34 and 8.5 +/- 1.12 while the wounds treated with EGF ointment with concentrations of 0.1 (HT100 = 6.4 +/- 0.71), 1 (HT100 = 5.2 +/- 0.63), 5 (HT100 = 5.8 +/- 0.85), 10 (HT100 = 7.1 +/- 1.45) and 25 ug/g (HT100 = 7.4 + 0.57) demonstrated significant reduction in time to achieve re-epithelialisation. Among the EGF-treated wounds, the wounds treated with EGF concentrations of 1 and 5 ug/g achieved the fastest re-epithelialisation with evidence of substantial increase in basal keratinocyte activity observed through Ki-67 activity. In conclusion, this article demonstrates the efficacy of human recombinant EGF in facilitating re-epithelialisation of partial thickness wounds with the most efficient healing found in EGF concentrations of 1 and 5 ug/g.

References

  1. Vet Pathol. 2003 Sep;40(5):574-8 [PMID: 12949417]
  2. Int Rev Cytol. 1996;169:151-81 [PMID: 8843654]
  3. Wound Repair Regen. 2000 May-Jun;8(3):162-8 [PMID: 10886806]
  4. Cell. 1987 Sep 25;50(7):1131-7 [PMID: 3497724]
  5. N Engl J Med. 1999 Sep 2;341(10):738-46 [PMID: 10471461]
  6. Wound Repair Regen. 1999 Sep-Oct;7(5):335-46 [PMID: 10564562]
  7. J Invest Dermatol. 1990 May;94(5):624-9 [PMID: 2324518]
  8. J Trauma. 1996 Jul;41(1):159-67 [PMID: 8676414]
  9. Clin Podiatr Med Surg. 1991 Oct;8(4):937-53 [PMID: 1933739]
  10. J Burn Care Rehabil. 1988 May-Jun;9(3):279-84 [PMID: 3262107]
  11. Am J Pathol. 1995 Nov;147(5):1261-77 [PMID: 7485390]
  12. Plast Reconstr Surg. 1991 Aug;88(2):189-94; discussion 195-6 [PMID: 1852809]
  13. Br J Surg. 2003 Feb;90(2):133-46 [PMID: 12555288]
  14. Plast Reconstr Surg. 1997 Sep;100(3):657-64 [PMID: 9283564]
  15. Annu Rev Biochem. 1979;48:193-216 [PMID: 382984]
  16. Clin Exp Dermatol. 1980 Mar;5(1):101-3 [PMID: 6967381]
  17. J Exp Med. 1986 May 1;163(5):1319-24 [PMID: 3486247]
  18. J Biol Chem. 1962 May;237:1555-62 [PMID: 13880319]
  19. Am J Surg. 1998 Aug;176(2A Suppl):74S-79S [PMID: 9777976]
  20. Ann Surg. 1988 Dec;208(6):788-94 [PMID: 3264140]
  21. Diabetes Care. 2003 Jun;26(6):1856-61 [PMID: 12766123]

MeSH Term

Administration, Topical
Animals
Disease Models, Animal
Dose-Response Relationship, Drug
Epidermal Growth Factor
Humans
Recombinant Proteins
Skin
Skin Diseases
Swine
Wound Healing
Wounds and Injuries

Chemicals

Recombinant Proteins
Epidermal Growth Factor

Word Cloud

Created with Highcharts 10.0.01woundsEGF50HT100+/-concentrations=re-epithelialisation104ug/gpartialthicknesstreatedhumanrecombinantgrowthfactorachieveeffect25demonstratedhealingtime87activityEpidermalpotentstimulantepithelialisationHowevertopicalapplicationfacilitatedcontroversialtotalpigseightxcmtwicedaydaysobservevehicletwocontrolscontrolvehicle-only100%9313412ointment6712638545+57significantreductionAmongEGF-treatedachievedfastestevidencesubstantialincreasebasalkeratinocyteobservedKi-67conclusionarticledemonstratesefficacyfacilitatingefficientfoundvariousepidermalsplit-thicknessskin

Similar Articles

Cited By (4)